Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
about
Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma : a meta-analysis of 37 trialsMonoclonal antibodies in the treatment of multiple myeloma: current status and future perspectivesNovel agents for multiple myeloma to overcome resistance in phase III clinical trialsTargeted treatments for multiple myeloma: specific role of carfilzomibA clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myelomaTrial Watch: Proteasomal inhibitors for anticancer therapyTriplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaPhase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary reSpecificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human CellsCarfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple MyelomaA phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myelomaCarfilzomib boosted combination therapy for relapsed multiple myelomaAssociation of response endpoints with survival outcomes in multiple myeloma.The emerging role of carfilzomib combination therapy in the management of multiple myeloma.New approaches to management of multiple myeloma.Carfilzomib in multiple myeloma.Novel agents and new therapeutic approaches for treatment of multiple myeloma.Current treatment landscape for relapsed and/or refractory multiple myeloma.An update on the use of lenalidomide for the treatment of multiple myeloma.Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making.Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma.Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.Emerging drugs and combinations to treat multiple myeloma.Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma.Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma.Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.Integration of Novel Agents into the Care of Patients with Multiple Myeloma.Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.
P2860
Q26741620-CFC3A356-DA08-471C-A9DC-72487C98DA4CQ26799104-78749F67-27A0-405A-AC8C-3E025CF8B17DQ26822754-208A3126-DEE9-4BE0-983F-590AABA62373Q26996524-375EEA34-5AC3-4D9D-86CF-DE6121326242Q28067148-F9C0871C-733B-4496-B296-5FF872F74BC9Q28082910-B7E904DE-4871-4C22-8957-1485DEDF1387Q30238893-4BD1C35B-B00A-45DA-998E-DF88177DC1F3Q30802505-C8E04F1D-EF48-4430-929C-D653D42ED6BAQ33410213-499B2F6A-0525-4F47-9DEC-90E26C7DDF97Q33412684-B8B955A5-FF08-4FFD-BBF1-E84A60E94C37Q33423168-113129FE-CDF0-4C88-84CD-B2B64AA3C5BAQ33430690-DD0C41BD-94F1-403D-B761-44662B64ABEDQ34788381-C216864C-C91A-44D7-A62F-9E81AA0E8135Q35895152-0BDC68DF-37D5-4492-AB31-ABCAC9F74144Q36020680-213A0787-B1AA-4142-ADBD-E08706A5789BQ36098363-288AA545-2DE3-4E6A-BAD2-62B5D6F22194Q36274834-32DFAB0B-48AB-4B31-ACF8-1CB776CEAB1BQ36444233-A116A6E4-F802-47A0-8AFD-72F9B5C146EAQ36671445-D820BEA3-A146-4C7A-B76A-4DCCBEED2BAEQ37652953-B2F52C26-E124-4E2F-8019-4058564C6236Q38122624-2A119C79-0F01-427E-95A7-DE85199C8D0CQ38187476-1E5FFA8F-D96A-4F02-95FC-5F9412C9F21DQ38191867-5A32463A-5F3D-4A58-9AA4-95B4D56DD201Q38244558-6ACA9282-A6F3-4C94-989D-88620CC5A1EFQ38261677-650B81F4-F177-4776-B369-D69328754746Q38271032-54F78092-7BEE-448E-BC70-8D865B96D970Q38545607-044C1F8D-6AE7-4013-A79B-97001BE5DFAEQ38896473-1755EFBB-1520-479D-B31B-AA77EF02B91DQ38989789-BA1946BA-2A08-40DE-A661-6911423707DBQ39124257-910D6562-A73A-4FEF-A12A-824A4BF1D3F0Q39138108-B7C2ECC7-7143-4A15-ACA9-F0573E78752DQ41531584-BD273587-1945-4386-8163-38437F2C8EC1Q41694198-D0AB92CF-7CA5-4D9A-922D-046F7E8293BFQ42004227-38AEFB30-632C-4B25-A20D-8824E881AF95Q42399854-CC60C963-DCF4-464E-85C8-5A9D180D850CQ42425704-2A5640B2-E7D5-4347-8513-C353C706A935Q43921722-5913A596-201A-47E8-A8E6-D4981485C018Q43994982-87BA0403-B944-4F5A-90E2-2F471B99809EQ46754093-3783E05F-3F81-4118-9526-827364E8ED01Q47236245-EEC230E0-5EF3-427B-AD3A-97F489DFF78C
P2860
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase Ib dose-escalation study ...... progressive multiple myeloma.
@ast
Phase Ib dose-escalation study ...... progressive multiple myeloma.
@en
type
label
Phase Ib dose-escalation study ...... progressive multiple myeloma.
@ast
Phase Ib dose-escalation study ...... progressive multiple myeloma.
@en
prefLabel
Phase Ib dose-escalation study ...... progressive multiple myeloma.
@ast
Phase Ib dose-escalation study ...... progressive multiple myeloma.
@en
P2093
P2860
P1476
Phase Ib dose-escalation study ...... progressive multiple myeloma.
@en
P2093
Alvin F Wong
David S Siegel
Lori A Kunkel
Melissa Alsina
Michael Wang
Thomas G Martin
William I Bensinger
P2860
P304
P356
10.1158/1078-0432.CCR-12-3352
P407
P577
2013-02-27T00:00:00Z